阿司匹林-蒙脱土-壳聚糖缓释微球的制备及其体外释放性能

利用溶液法预先制备壳聚糖(Cs)-蒙脱土(MMT)复合材料(Cs-MMT),以Cs-MMT、Cs为原料,采用反相悬浮聚合法制得一种新型药物缓释体系阿司匹林-蒙脱土-壳聚糖载药微球(Asp-MMT-Cs)。采用FT-IR、SEM表征了Cs-MMT和Asp-MMT-Cs载药微球的结构及形态;设计正交实验优化了Asp-MMT-Cs载药微球的制备工艺;通过体外释放实验探讨了载药微球在不同模拟释放液中的释药规律。结果表明:所得微球球形度好,粒径分布较均匀;最优工艺制得的载药微球平均粒径为81.20μm,载药量为9.61%,包封率为76.78%。该缓释体系具有pH敏感性,更倾向于在pH较高的磷酸盐缓冲溶液中释放。     

酸碱处理蒙脱土与磷酸酯阻燃剂复配阻燃PC/ABS合金

采用酸碱处理法对蒙脱土进行有机化改性, 再将酸碱处理的蒙脱土与磷酸酯阻燃剂复配, 作为聚碳酸酯/丙烯腈-丁二烯-苯乙烯三元共聚物(PC/ABS)合金的阻燃体系, 并表征了酸碱处理蒙脱土对合金的热稳定性和阻燃性能. 结果表明, 间苯二酚双(二苯基磷酸酯)改性的蒙脱土(BDP-MMT)使阻燃PC/ABS合金的起始分解温度降低, 而酸碱处理蒙脱土却使合金的起始分解温度有所提高; BDP-MMT的加入会恶化碳层的阻隔性能, 而酸碱处理蒙脱土却可以增加碳层的稳定性, 使第二热释放峰值出现的时间延迟, 且适合的酸浓度处理蒙脱土可以使合金通过UL-94 V-0级检验.     

有机硅/蒙脱土复合改性聚氨酯弹性体的制备和性能

采用先将聚醚三元醇N330与有机蒙脱土(OMMT)研磨,制得N330/OMMT复合物,再将其与有机硅改性聚氨酯的预聚体混合的方法,以二甲硫基甲苯二胺(DMTDA)为固化剂,制备了有机硅/蒙脱土复合改性聚氨酯弹性体,并用FTIR对产物结构进行了表征.XRD和TEM表明,蒙脱土片层被撑开,并分散在基体中;SEM显示,加入蒙脱土后,有机硅与聚氨酯之间的相容性提高;TGA表明,有机硅和OMMT共同改性聚氨酯后,其耐热性比有机硅单一改性聚氨酯有所提高,并在OMMT含量为5 wt％时提高最大;DSC数据表明,在OMMT含量为5 wt％时,有机硅/蒙脱土复合改性聚氨酯弹性体的Tg明显升高.复合改性材料具有良好的表面性能和力学性能,其拉伸强度、断裂伸长率和硬度在OMMT含量为3 wt％时达到最大值.     

非甾体类药物含糖乙烯醇酯共聚物制备及药物释放研究

分别利用化学法和酶促法合成了三种药物(萘普生、酮洛芬、布洛芬)乙烯酯和葡萄糖丁二酸乙烯酯(6-O-乙烯丁二酰-D-葡萄糖)两种聚合单体, 通过两种单体的自由基聚合反应制备了具有较高分子量的含糖聚合物前药. 通过IR、NMR对聚合物的结构进行了表征, 用GPC测定共聚物分子量. 含糖聚合物前药的体外释放研究表明, 将小分子原药制备成含糖聚合物前药后, 药物的释放时间大大延长, 达到了缓释的目的. 三种含糖聚合物的药物释放研究表明, 酮洛芬含糖高分子前药的药物释放速率较快, 萘普生含糖高分子前药的药物释放速率较慢. 不同的pH条件下的含糖聚合物的药物释放研究表明, 碱性环境下的药物释放较快, 酸性环境下的药物释放较慢.     

七、八元瓜环对盐酸雷尼替丁的包合作用及缓释性能

研究了七元瓜环(Q[7])和八元瓜环(Q[8])与盐酸雷尼替丁(RH)的包合作用及包合物的体外药物缓释性能.采用紫外-可见光谱法测定了体系的包合比、包合稳定常数和药物累积释放度;用1H NMR技术考察了体系主-客体的包合作用.结果表明,Q[7]和Q[8]与RH在酸性及中性条件下均能发生1∶1包合作用,包合稳定常数分别为1.21×104和2.06×104 L/mol;在碱性条件下则不发生包合作用.原药RH,Q[7]-RH及Q[8]-RH包合物在人工胃液(pH=1.2)中的60 min累积释放度分别为89.1%,56.6%和38.4%;而在人工肠液(pH=6.8)中三者的60 min累积释放度分别为90.2%,58.7%和38.0%.实验结果表明,Q[7]及Q[8]包合对RH有明显的体外缓释作用.     

ZIF-8的制备及其作为杀菌药物载体的研究

采用室温搅拌法制备了金属有机骨架材料ZIF-8.通过X射线粉末衍射(XRD)、红外光谱(IR)、N2吸附-脱附、透射电子显微镜(TEM)和扫描电子显微镜(SEM)对所得样品进行了表征分析,并以苯扎氯铵为杀菌药物模型,研究了ZIF-8对苯扎氯铵这种药物的载药及体外释药性能.表征结果显示,制备的ZIF-8是一种具有规则十二面体方钠石结构的晶体,BET比表面积为2 643m2/g.载药及体外释放实验表明,ZIF-8对浓度为4mmol/L苯扎氯铵的载药量为43g/100g ZIF-8,载药后的ZIF-8在释放90h后,释放率达84.82%,说明ZIF-8对苯扎氯铵有较好的缓释性能.     

基于HPMCP包覆介孔SBA-15的pH敏感药物缓释系统

以肠溶性包衣材料羟丙甲纤维素邻苯二甲酸酯(HPMCP)为原料,在负载法莫替丁(Famo)的SBA-15药片表面包覆聚合物膜,成功制备了一种新型的pH敏感药物缓释系统, 并考察了此缓释系统在不同pH释放环境中的释放行为. 结果表明: 在模拟胃液中(SGF, pH=1.2),HPMCP能致密包覆在药片表面,从而明显延缓Famo的释放速度;而在模拟肠液中(SIF, pH=7.5),HPMCP能够迅速溶于缓释溶液中,因而对Famo释放速度的影响甚微. 因此,可以将这种新型智能药物缓释系统应用于肠道靶向给药.     

聚N,N-二乙基丙烯酰胺蒙脱土纳米复合物的合成及溶胀性能

在制成钠基蒙脱土的基础上 ,对蒙脱土进行了改性 ,并把改性后的蒙脱土分散在N ,N 二乙基丙烯酰胺水溶液中进行聚合 .结果表明这种蒙脱土插层聚合的水凝胶的低温溶胀性能大大提高 ,其对水的释放曲线在特定的温度下也由S形转变为近一直线形 .由于蒙脱土的改性 ,在蒙脱土和聚合物之间的界面化学发生了改变 ,用X衍射分析表明此水凝胶是纳米复合材料 .而加入蒙脱土量达 10 %的水凝胶的溶胀比和温度响应性能也都发生很大改善 .     

sPS/PA6/蒙脱土纳米复合材料的制备与性能

讨论了间规聚苯乙烯 (sPS) 尼龙 6(PA6) 磺化间规聚苯乙烯 (SsPS H) 蒙脱土纳米复合材料的制备技术和新材料的结构与性能特征 .蒙脱土经层间改性处理后 (MTN) ,可分别将SsPS H和aPS(无规聚苯乙烯 )插入其纳米层间 ,制备出插层型纳米复合物MTN SsPS和MTN aPS .在sPS/PA6/SsPS H三组分共混体系中加入MTN SsPS或MTN aPS ,进行四组分熔融共混即可制备出sPS/PA6/SsPS H/蒙脱土纳米复合材料 .TEM测定证实了蒙脱土在基体中的层厚分布约为 5 0nm .此外 ,采用DSC、DMA、XRD及力学性能测试仪等现代分析方法对sPS/PA6/SsPS H/蒙脱土纳米复合材料的结构与性能进行了详细研究 .研究结果表明这种纳米复合材料具有优良的综合性能     

基于胶束插层方法制备高热稳定性和大层间距有机化蒙脱土

采用不同方法制备了多种有机化蒙脱土,并分别采用X射线衍射仪、红外光谱分析仪、热重分析仪、电感耦合等离子体发射光谱仪、元素分析仪、扫描电子显微镜对产物进行了表征,并提出了有机物插层新方式——胶束插层.结果表明:适量钠基蒙脱土(Na-MMT)、十六烷基三甲基溴化铵(CTAB)和磷酸三苯酯(TPP)在丙酮/水的混合溶剂中进行溶液插层,得到的有机化蒙脱土具有更大的层间距,比单纯采用CTAB的插层效果显著.产物中含有约21.54%的CTAB和17.47±1.05%的TPP,插层机理为CTAB-TPP胶束插层.该有机化蒙脱土的初始热降解温度比单纯CTAB插层蒙脱土最多提高了17.4℃.采用该方法制备的改性蒙脱土既可以进一步提高蒙脱土的层间距,又可以封闭TPP于MMT的片层间,阻止TPP挥发;同时克服季铵盐改性蒙脱土的热稳定性低的问题,得到了层间距大、热稳定性高的有机化蒙脱土,为有机化蒙脱土在高熔点聚合物改性方面提供了条件.     

八元瓜环与常山碱的相互作用模式

利用紫外吸收光谱、 荧光光谱、 核磁共振氢谱及红外光谱等方法考察了八元瓜环(Q[8])对常山碱(Feb)的包结作用; 采用紫外吸收光谱法研究了Q[8]对Feb理化性质的影响及不同pH条件下Q[8]/Feb包合物溶液中Feb的释放及Q[8]/Feb包合物在人工肠液和人工胃液中的释放. 结果表明, 在pH=1.2的盐酸介质中, Q[8]与Feb可形成摩尔比1∶1的稳定主客体包合物, 结合常数为4.20×10 ⁴ L/mol. 在pH=1.2(人工胃液的pH值)时, Feb可与Q[8]形成稳定包合物; 在pH=6.8(人工肠液的pH值)时, Q[8]/Feb包合物可释放出单纯的游离Feb. 因此, Q[8]可作为Feb的一种潜在药物载体为减轻Feb呕吐副反应提供借鉴.     

抗癌载药体系Fe_3O_4@ZIF-8@PA的合成及药物释放

采用溶剂热法合成磁性Fe_3O_4纳米粒子,并以此为基底设计制备了一种具有pH响应核壳结构的磁性纳米复合材料Fe_3O_4@ZIF-8@PA.该材料的比饱和磁化强度可达35.46 A·m2/g,具有良好的磁性.Fe_3O_4纳米粒子呈球型结构,分散性良好.与基底相比,复合微球的粒径尺寸明显增大,但依然符合载体材料的理想尺寸且分布均匀.此外,载体具有多孔结构,表面积较大,载药效率和载药量分别高达96.4%和144.6 mg/g.在pH为7.4和5.0的条件下对载药纳米粒子进行了药物释放研究.24 h内,粒子在2种pH下累计释放量分别为39.8%和78.6%.通过药物缓释验证了载体的pH响应性能.在实验中引入了对癌细胞具有杀伤作用的植酸,使合成的载体具有一定的抗癌作用.同时采用四甲基偶氮唑盐(MTT)法对人骨肉瘤细胞(MG-63)进行了体外分析实验,证实材料与抗癌药物阿霉素(DOX)之间存在着一定的协同抗癌效果.     

Preparation and evaluation of nano-hydroxyapatite/poly(styrene-divinylbenzene) porous microsphere for aspirin carrier

A novel vehicle for the delivery of aspirin (ASA) was prepared from porous nano-hydroxyapatite/poly(styrene-divinylbenzene) [nano-HAP/P(St-DVB)] composite microspheres by grafting nano-HAP [Ca10(PO4)6(OH)2] onto porous P(St-DVB) microspheres. Four types of porous composite microspheres were prepared, each with different nano-HAP contents. The ASA-loaded composite microspheres prepared with 10% and 15% nano-HAP (mass ratio) exhibited excellent buoyancy with relatively short instantaneous floating time (within 10 min) and a long sustained floating time (12 h) in simulated gastric juice. They also offered good sustained release of ASA (up to 8 h). Furthermore, these composite microspheres displayed good buffering capacity that prevented the buildup of acidity caused by hydrolysis of ASA, keeping the pH of gastric juice within the normal range (pH 0.9 to 1.5). The results showed that porous nano-HAP/P(St-DVB) composite microspheres prepared with 10% and 15% nano-HAP could be used as a novel drug carrier for ASA, providing a sustained release dose without leading to stomach irritation, a side effect that is often associated with ASA medication.     

Synthesis and characterization of a pH responsive and mucoadhesive drug delivery system for the controlled release application of anti-cancerous drug

In this work a novel pH sensitive composite, polyacrylamide grafted succinyl chitosan intercalated bentonite (AAm-g-NB/SC) was prepared as a drug carrier system for the controlled delivery of paclitaxel. Characterization of the drug delivery system was carried out using Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), thermal analysis etc. The equilibrium swelling behaviour of the composite was studied and the result showed a maximum at pH 7.4. The in vitro drug release study of paclitaxel indicated that about 15.6% of drug release was found to be occurred at pH 1.2 within 16 h, whereas about 82.5% of drug release was occurred at the intestinal pH condition of 7.4. In vitro biocompatibility study was performed and the result showed good biocompatibility of the composite in the concentration range 6.25–100 µg/mL. The cytotoxicity assay was carried out in cancerous cell line of Human colorectal Adenocarcinoma. Mucous glycoprotein assay study showed that the drug delivery system having good apparent adhering property towards mucin. The investigation indicated that paclitaxel, an anticancer drug can be successfully entrapped in the AAm-g-NB/SC composite for the controlled and targeted delivery for colorectal cancer therapy.     

Clinoptilolite Microparticles as Carriers of Catechin-Rich Acacia catechu Extracts: Microencapsulation and In Vitro Release Study

The main goal of the present study was to investigate the microencapsulation, in vitro release capacity and efficiency of catechin-rich Acacia catechu extract by Clinosorbent-5 (CLS-5) microparticles by in-depth detailed analyses and mathematical modelling of the encapsulation and in vitro release kinetics behaviour of the polyphenol-mineral composite system. The bioflavanol encapsulation and release efficiency on/from the mineral matrix were assessed by sorption experiments and interpretative modelling of the experimental data. The surface and spectral characteristics of the natural bioactive substance and the inorganic microcarrier were determined by Fourier Transform Infrared Spectroscopy (FTIR) and Ultraviolet/Visible (UV/Vis) spectrophotometric analyses. The maximum extent of catechin microencapsulation in acidic medium was 32%. The in vitro release kinetics study in simulated enzyme-free gastric medium (pH = 1.2) approved 88% maximum release efficiency achieved after 24 h. The in vitro release profile displayed that the developed bioflavanol/clinoptilolite microcarrier system provided sustained catechin in vitro release behaviour without an initial burst effect. Thus, the results from the present study are essential for the design and development of innovative catechin-CLS-5 microcarrier systems for application in human and veterinary medicine.     

Chitosan nanoparticles crosslinked by glycidoxypropyltrimethoxysilane for pH triggered release of protein

pH-responsive-chitosan nanoparticles for the control release of protein drug were prepared by combining two-step crosslinking method,in which chitosan was subsequently crosslinked by sodium tripolyphosphate(TPP)and glycidoxypropyltrimethoxysilane (GPTMS).Compared with TPP crosslinked chitosan particles,the two-step crosslinked nanoparticles were not only pH-responsive but also more stable in wide pH range.Fluorescein isothiocyanate(FITC)labeled anti-human-IgG antibody was used as a model protein drug for...     

壳聚糖-聚丙烯酸复合水凝胶的药物控制释放行为

以壳聚糖(Cs)和丙烯酸(AA)为原料,利用自由基聚合法制备了具有孔洞结构的复合水凝胶Cs-PAA,并研究了AA的量、交联剂的量、聚合温度和AA的中和度对水凝胶溶胀度的影响以及复合水凝胶对烟酸的控制释放。 结果表明,Cs-PAA复合水凝胶具有良好的pH值、离子强度敏感性,且溶胀度最高达1228 g/g,其在pH=686的缓冲溶液中的烟酸累积释放率明显大于其在pH=1.80的缓冲溶液,因此Cs-PAA水凝胶可作为肠口服药物的载体。     

Synthesis, characterization and sustaining controlled release effect of mesoporous SBA-15/ramipril composite drug

A loading of ramipril in SBA-15 (Santa Barbara Amorphous) mesoporous material was studied. (SBA-15)-ramipril composite material was characterized by chemical analysis, infrared spectroscopy, powder X-ray diffraction, low temperature N₂ adsorption–desorption at 77 K characterization techniques. Ramipril drug release processes from SBA-15 host to simulated body fluid (SBF), simulated gastric juice (SGJ), simulated intestinal fluid (SIF) were monitored in a simulated way and actions of the sustained release of (SBA-15)-ramipril was studied. The results showed that the loading amount of ramipril drug in SBA-15 was 90.30 mg/g. The cumulative sustained release rate of ramipril composite drug in SBF achieved 99.7 % after 27 h. When the sustained release of composite drug in SGJ was 8 h, the maximum cumulative sustained release ratio achieved 54.9 %. When the sustained release of composite drug was 9 h in SIF, the maximum cumulative sustained release ratio achieved 34.9 %. The method described in this study is suitable for carrying ramipril drug on SBA-15, and a new carrier to load ramipril drug was found. Meanwhile, the efficacy of ramipril drug and time efficacy could be improved.     

离子凝聚法制备负载流感疫苗的壳聚糖微球

采用三聚磷酸钠(TPP)作为离子交联剂, 应用离子凝聚法制备负载流感疫苗的壳聚糖微球. 筛选出壳聚糖起始质量分数为1%. TPP的浓度对壳聚糖微球的制备影响较大, 采用低浓度的TPP(200 μg/mL)制备的微球放置过夜均出现沉淀现象, 高浓度的TPP(800 μg/mL)在制备过程中出现絮状沉淀. 固化比影响微球的释放行为, 固化比为1∶1的微球爆炸式释放率达到90％, 固化比为1∶3的微球6 h后逐步释放, 12 h后释放率达到95％. 固化比为1∶5的微球6 h后没有明显的释放行为. 壳聚糖溶液的pH对微球的制备和释放没有显著的影响. 通过对负载流感疫苗的壳聚糖微球的制备条件和释放行为的研究结果表明, pH=5.6的壳聚糖溶液, 固化比为1∶3, TPP的质量浓度为400 μg/mL是较理想的流感疫苗壳聚糖微球的制备条件.